Northwest Quadrant Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $496K | Buy |
1,972
+12
| +0.6% | +$2.58K | 0.09% | 39 |
|
|
2026
Q1 | $426K | Buy |
1,960
+12
| +0.6% | +$2.66K | 0.09% | 35 |
|
|
2025
Q4 | $445K | Buy |
1,948
+11
| +0.6% | +$2.51K | 0.09% | 37 |
|
|
2025
Q3 | $448K | Buy |
1,937
+92
| +5% | +$18.7K | 0.09% | 38 |
|
|
2025
Q2 | $342K | Buy |
1,845
+13
| +0.7% | +$2.42K | 0.08% | 43 |
|
|
2025
Q1 | $384K | Sell |
1,832
-46
| -2% | -$8.94K | 0.09% | 37 |
|
|
2024
Q4 | $334K | Buy |
1,878
+13
| +0.7% | +$2.39K | 0.08% | 48 |
|
|
2024
Q3 | $368K | Buy |
1,865
+11
| +0.6% | +$2.05K | 0.08% | 40 |
|
|
2024
Q2 | $318K | Buy |
1,854
+14
| +0.8% | +$2.32K | 0.08% | 40 |
|
|
2024
Q1 | $335K | Buy |
1,840
+12
| +0.7% | +$2.07K | 0.08% | 44 |
|
|
2023
Q4 | $283K | Buy |
1,828
+182
| +11% | +$26.5K | 0.07% | 47 |
|
|
2023
Q3 | $245K | Buy |
1,646
+13
| +0.8% | +$1.91K | 0.07% | 50 |
|
|
2023
Q2 | $220K | Buy |
1,633
+12
| +0.7% | +$1.76K | 0.06% | 53 |
|
|
2023
Q1 | $258K | Buy |
1,621
+11
| +0.7% | +$1.68K | 0.07% | 48 |
|
|
2022
Q4 | $260K | Sell |
1,610
-73
| -4% | -$11.2K | 0.08% | 50 |
|
|
2022
Q3 | $226K | Buy |
1,683
+53
| +3% | +$7.61K | 0.07% | 49 |
|
|
2022
Q2 | $251K | Sell |
1,630
-291
| -15% | -$44.5K | 0.08% | 52 |
|
|
2022
Q1 | $311K | Sell |
1,921
-123
| -6% | -$17.9K | 0.09% | 45 |
|
|
2021
Q4 | $277K | Buy |
2,044
+12
| +0.6% | +$1.42K | 0.07% | 50 |
|
|
2021
Q3 | $221K | Buy |
2,032
+97
| +5% | +$11.1K | 0.06% | 62 |
|
|
2021
Q2 | $217K | Buy |
1,935
+12
| +0.6% | +$1.35K | 0.06% | 63 |
|
|
2021
Q1 | $208K | Buy |
1,923
+13
| +0.7% | +$1.39K | 0.06% | 61 |
|
|
2020
Q4 | $201K | Buy |
+1,910
| New | +$184K | 0.07% | 60 |
|
|
2020
Q3 | – | Sell |
-2,185
| Closed | -$211K | – | 56 |
|
|
2020
Q2 | $211K | Sell |
2,185
-186
| -8% | -$16.4K | 0.09% | 54 |
|
|
2020
Q1 | $200K | Buy |
2,371
+15
| +0.6% | +$1.28K | 0.09% | 54 |
|
|
2019
Q4 | $209K | Buy |
+2,356
| New | +$196K | 0.09% | 66 |
|
|
2019
Q2 | – | Sell |
-2,652
| Closed | -$214K | – | 63 |
|
|
2019
Q1 | $214K | Buy |
2,652
+7
| +0.3% | +$573 | 0.1% | 58 |
|
|
2018
Q4 | $204K | Buy |
2,645
+68
| +3% | +$5.98K | 0.1% | 57 |
|
|
2018
Q3 | $226K | Buy |
2,577
+302
| +13% | +$28.6K | 0.14% | 47 |
|
|
2018
Q2 | $211K | Buy |
+2,275
| New | +$222K | 0.14% | 51 |
|
Other funds holding ABBV
Northwest Quadrant Wealth Management's ABBV Position: Q2 2026 in Review
Northwest Quadrant Wealth Management increased its AbbVie (ABBV) stake by 0.61% in Q2 2026, buying an estimated $2.58K and bringing the position to 1,972 shares worth $496K. The position accounts for 0.09% of the portfolio, ranked #39.
Northwest Quadrant Wealth Management first reported a position in ABBV in Q2 2018 and has held it in 30 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Northwest Quadrant Wealth Management held 1,972 shares of AbbVie worth $496K as of Q2 2026.
- Northwest Quadrant Wealth Management bought 12 AbbVie shares in Q2 2026, an estimated $2.58K.
- AbbVie made up 0.09% of Northwest Quadrant Wealth Management's portfolio in Q2 2026, its #39 holding.
- Northwest Quadrant Wealth Management first reported a position in AbbVie in Q2 2018 and has held it in 30 quarters since.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Northwest Quadrant Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.